vs
Envela Corp（ELA）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
Envela Corp的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.1倍（$80.5M vs $75.5M），Envela Corp同比增速更快（66.6% vs 27.7%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $-3.7M），过去两年Envela Corp的营收复合增速更高（42.1% vs 31.3%）
Envela Corp是一家总部位于美国的企业，核心开展再流通业务，致力于延长产品生命周期、减少资源消耗。公司业务主要分为两大板块，分别面向个人消费者端与企业商业端，通过盘活二手资源实现可持续的商业价值。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
ELA vs PBYI — 直观对比
营收规模更大
ELA
是对方的1.1倍
$75.5M
营收增速更快
ELA
高出38.9%
27.7%
自由现金流更多
PBYI
多$18.1M
$-3.7M
两年增速更快
ELA
近两年复合增速
31.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $80.5M | $75.5M |
| 净利润 | $6.0M | — |
| 毛利率 | 20.5% | 69.3% |
| 营业利润率 | 9.4% | 22.7% |
| 净利率 | 7.4% | — |
| 营收同比 | 66.6% | 27.7% |
| 净利润同比 | 274.6% | — |
| 每股收益（稀释后） | $0.22 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ELAPBYI
| Q4 25 | $80.5M | $75.5M | ||
| Q3 25 | $57.4M | $54.5M | ||
| Q2 25 | $54.9M | $52.4M | ||
| Q1 25 | $48.3M | $46.0M | ||
| Q4 24 | $48.3M | $59.1M | ||
| Q3 24 | $46.9M | $80.5M | ||
| Q2 24 | $45.3M | $47.1M | ||
| Q1 24 | $39.9M | $43.8M |
净利润ELAPBYI
| Q4 25 | $6.0M | — | ||
| Q3 25 | $3.4M | $8.8M | ||
| Q2 25 | $2.8M | $5.9M | ||
| Q1 25 | $2.5M | $3.0M | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $1.7M | $20.3M | ||
| Q2 24 | $1.6M | $-4.5M | ||
| Q1 24 | $1.9M | $-4.8M |
毛利率ELAPBYI
| Q4 25 | 20.5% | 69.3% | ||
| Q3 25 | 22.8% | 77.7% | ||
| Q2 25 | 22.6% | 76.5% | ||
| Q1 25 | 24.8% | 77.1% | ||
| Q4 24 | 23.1% | 76.4% | ||
| Q3 24 | 24.4% | 63.9% | ||
| Q2 24 | 25.1% | 77.4% | ||
| Q1 24 | 25.9% | 75.5% |
营业利润率ELAPBYI
| Q4 25 | 9.4% | 22.7% | ||
| Q3 25 | 7.3% | 17.6% | ||
| Q2 25 | 5.9% | 12.7% | ||
| Q1 25 | 6.5% | 8.7% | ||
| Q4 24 | 3.9% | 22.6% | ||
| Q3 24 | 4.3% | 27.4% | ||
| Q2 24 | 4.2% | -4.6% | ||
| Q1 24 | 5.9% | -5.3% |
净利率ELAPBYI
| Q4 25 | 7.4% | — | ||
| Q3 25 | 5.8% | 16.2% | ||
| Q2 25 | 5.0% | 11.2% | ||
| Q1 25 | 5.2% | 6.5% | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 3.6% | 25.2% | ||
| Q2 24 | 3.5% | -9.6% | ||
| Q1 24 | 4.8% | -11.0% |
每股收益（稀释后）ELAPBYI
| Q4 25 | $0.22 | $0.26 | ||
| Q3 25 | $0.13 | $0.17 | ||
| Q2 25 | $0.11 | $0.12 | ||
| Q1 25 | $0.10 | $0.06 | ||
| Q4 24 | $0.07 | $0.40 | ||
| Q3 24 | $0.06 | $0.41 | ||
| Q2 24 | $0.06 | $-0.09 | ||
| Q1 24 | $0.07 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $97.5M |
| 总债务越低越好 | $9.9M | $22.7M |
| 股东权益账面价值 | $67.1M | $130.3M |
| 总资产 | $96.0M | $216.3M |
| 负债/权益比越低杠杆越低 | 0.15× | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资ELAPBYI
| Q4 25 | — | $97.5M | ||
| Q3 25 | — | $94.4M | ||
| Q2 25 | — | $96.0M | ||
| Q1 25 | — | $93.2M | ||
| Q4 24 | — | $101.0M | ||
| Q3 24 | — | $96.7M | ||
| Q2 24 | — | $96.8M | ||
| Q1 24 | $19.8M | $107.2M |
总债务ELAPBYI
| Q4 25 | $9.9M | $22.7M | ||
| Q3 25 | $12.5M | $34.0M | ||
| Q2 25 | $13.0M | $45.3M | ||
| Q1 25 | $13.2M | $56.7M | ||
| Q4 24 | $13.5M | $68.0M | ||
| Q3 24 | $13.8M | $79.3M | ||
| Q2 24 | $14.3M | $90.7M | ||
| Q1 24 | $14.6M | $102.0M |
股东权益ELAPBYI
| Q4 25 | $67.1M | $130.3M | ||
| Q3 25 | $61.1M | $115.3M | ||
| Q2 25 | $57.8M | $104.7M | ||
| Q1 25 | $55.1M | $97.1M | ||
| Q4 24 | $52.7M | $92.1M | ||
| Q3 24 | $51.1M | $71.1M | ||
| Q2 24 | $50.2M | $48.5M | ||
| Q1 24 | $49.3M | $51.0M |
总资产ELAPBYI
| Q4 25 | $96.0M | $216.3M | ||
| Q3 25 | $90.9M | $202.9M | ||
| Q2 25 | $82.7M | $194.9M | ||
| Q1 25 | $79.7M | $196.2M | ||
| Q4 24 | $77.9M | $213.3M | ||
| Q3 24 | $77.4M | $220.7M | ||
| Q2 24 | $73.8M | $205.0M | ||
| Q1 24 | $74.7M | $214.1M |
负债/权益比ELAPBYI
| Q4 25 | 0.15× | 0.17× | ||
| Q3 25 | 0.20× | 0.30× | ||
| Q2 25 | 0.23× | 0.43× | ||
| Q1 25 | 0.24× | 0.58× | ||
| Q4 24 | 0.26× | 0.74× | ||
| Q3 24 | 0.27× | 1.12× | ||
| Q2 24 | 0.29× | 1.87× | ||
| Q1 24 | 0.30× | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.5M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $-3.7M | $14.4M |
| 自由现金流率自由现金流/营收 | -4.6% | 19.1% |
| 资本支出强度资本支出/营收 | 0.2% | 0.0% |
| 现金转化率经营现金流/净利润 | -0.59× | — |
| 过去12个月自由现金流最近4个季度 | $1.4M | $41.7M |
8季度趋势，按日历期对齐
经营现金流ELAPBYI
| Q4 25 | $-3.5M | $14.4M | ||
| Q3 25 | $2.4M | $9.7M | ||
| Q2 25 | $2.6M | $14.1M | ||
| Q1 25 | $1.1M | $3.6M | ||
| Q4 24 | $3.7M | $15.6M | ||
| Q3 24 | $3.4M | $11.0M | ||
| Q2 24 | $-789.5K | $1.0M | ||
| Q1 24 | $3.8M | $11.2M |
自由现金流ELAPBYI
| Q4 25 | $-3.7M | $14.4M | ||
| Q3 25 | $2.2M | $9.7M | ||
| Q2 25 | $2.1M | $14.1M | ||
| Q1 25 | $746.6K | $3.6M | ||
| Q4 24 | $3.2M | $15.6M | ||
| Q3 24 | $1.5M | $11.0M | ||
| Q2 24 | $-1.3M | $1.0M | ||
| Q1 24 | $3.3M | — |
自由现金流率ELAPBYI
| Q4 25 | -4.6% | 19.1% | ||
| Q3 25 | 3.8% | 17.7% | ||
| Q2 25 | 3.9% | 26.8% | ||
| Q1 25 | 1.5% | 7.7% | ||
| Q4 24 | 6.7% | 26.4% | ||
| Q3 24 | 3.1% | 13.7% | ||
| Q2 24 | -2.9% | 2.1% | ||
| Q1 24 | 8.4% | — |
资本支出强度ELAPBYI
| Q4 25 | 0.2% | 0.0% | ||
| Q3 25 | 0.4% | 0.0% | ||
| Q2 25 | 0.8% | 0.0% | ||
| Q1 25 | 0.8% | 0.1% | ||
| Q4 24 | 1.0% | 0.0% | ||
| Q3 24 | 4.2% | 0.0% | ||
| Q2 24 | 1.1% | 0.0% | ||
| Q1 24 | 1.1% | 0.0% |
现金转化率ELAPBYI
| Q4 25 | -0.59× | — | ||
| Q3 25 | 0.72× | 1.10× | ||
| Q2 25 | 0.94× | 2.41× | ||
| Q1 25 | 0.45× | 1.21× | ||
| Q4 24 | 2.34× | — | ||
| Q3 24 | 2.05× | 0.54× | ||
| Q2 24 | -0.50× | — | ||
| Q1 24 | 1.99× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ELA
| Consumer Segment | $67.7M | 84% |
| Commercial Segment | $12.8M | 16% |
PBYI
暂无分部数据
